As the fourth quarter kicks off, I’ve prepared a checklist of jobs that retirement savers (that is, those who are at least a ...

AstraZeneca reached a deal valued at up to $2.02 billion to license an experimental therapy for a disorder affecting cholesterol and related cardiovascular diseases from CSPC Pharmaceutical Group.

Richemont took control of YNAP in 2018, three years after the business was formed through the merger of Italian e-commerce firm Yoox and London-based Net-a-Porter, in a move that sought to capture the ...

Stocks in Europe were lower on Monday as investors looked for fresh direction at the start of another busy week.

Morgan Stanley strategists led by Mike Wilson say the reaction on Friday was to be expected, because the market is currently is in a "good is good" environment - which is demonstrated now by the ...

My cousins justify their opinion on the matter given that their father saved the business from going under - there's no proof of this, of course. To me, it feels like a justification to keep my father ...

Investors are looking to extend Friday's rally on hopes for a soft landing for the economy. German manufacturing orders fell almost 6% in August, much more than expected, furthering pressure on the ...

Why Tesla's Wall Street Valuations Are All Over the Place The company makes electric vehicles, has an energy storage business, and invests in artificial intelligence. That makes figuring out what its ...

Last quarter, lower refining margins drove a 33% drop in Shell's chemicals segment's adjusted earnings. The company said Monday that performance is expected to be even lower in the third quarter, with ...

Former New York City mayor Rudy Giuliani is racing against time to offload his Upper East Side condo, slashing the price by nearly $1 million in a desperate attempt to find a buyer. The embattled ...

"Only Murders in the Building" star Selena Gomez, who is also an entrepreneur and a singer, can add one more title to her list of accomplishments: billionaire. The star is worth a jaw-dropping $1.3 ...

AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.